Related Experiment Video

Updated: Mar 11, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K

Chagas Cardiomyopathy: Clinical Presentation and Management in the Americas

Catherine Pastorius Benziger1, Gabriel Assis Lopes do Carmo2, Antonio Luiz Pinho Ribeiro3

  • 1Division of Cardiology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.

Cardiology Clinics
|November 26, 2016
PubMed

Insights

Chagas disease can lead to serious cardiac or gastrointestinal issues. Early detection and prevention strategies are crucial for managing this neglected tropical disease and reducing its global impact.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Public Health

Background:

  • Chagas disease, caused by *Trypanosoma cruzi*, often presents asymptomatically initially.
  • A significant percentage of infected individuals develop chronic cardiac or gastrointestinal complications.
  • Sudden death can occur due to arrhythmias or heart failure in advanced stages.

Purpose of the Study:

  • To provide a comprehensive overview of Chagas cardiac disease for healthcare professionals.
  • To educate primary care providers and cardiologists in non-endemic regions on diagnosis and management.
  • To emphasize the importance of prevention and surveillance in controlling Chagas disease.

Main Methods:

  • Review of epidemiology, diagnostic evaluation, diagnosis, and treatment protocols for Chagas cardiac disease.
  • Focus on clinical presentation and management strategies for acute and chronic forms.
  • Discussion of public health interventions including vector control and blood screening.

Main Results:

  • Chagas disease has diverse clinical manifestations, with cardiac involvement being a major concern.
  • Effective management requires understanding the disease's progression and specific diagnostic tools.
  • Prevention and surveillance are vital for global disease burden reduction.

Conclusions:

  • Educating healthcare professionals, especially in non-endemic areas, is essential for timely diagnosis and treatment.
  • Integrated strategies encompassing vector control, screening, and surveillance are key to combating Chagas disease.
  • Prompt recognition and management of Chagas cardiac disease can mitigate severe outcomes and improve patient prognosis.

Keywords:
CardiomyopathyChagas diseaseEpidemiologyNeglected diseasesTrypanocidal agents

More Related Videos

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

2.2K
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

15.7K

Related Concept Videos

Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
433
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
743
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
698
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
286